Interview: Madhusudhan Venkatachari – CEO, Natco Pharma Canada
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Address: NATCO HOUSERoad No.2, Banjara HillsHyderabad-500 033,India
Tel: +91-40-2354 7532
Web: http://www.natcopharma.co.in/
NATCO Pharma Limited is an Indian enterprise molded by global aspirations. This has always demanded a preparedness and long- term organizational vision that can encompass the turbulence’s and paradoxes of shifting terms and terrain’s of business.
Background
Beginning:- NATCO PHARMA was promoted by Mr. V.C. Nannapaneni in the year 1981 as a Private Limited Company to be in the business of Research, Developing, Manufacturing and Marketing of Pharmaceutical Substances and Finished Dosage forms for Indian and International markets. NATCO PHARMA began operations in 1984 in Andhra Pradesh, India.
First Success:- In the first year of its operations it achieved a sales figure of Rs. 0.5 million. The company’s first product was Cardicap, which is an Anti-Anginal drug. Since then the company has introduced many dosage forms into the market. By 1985 it had dosage forms in Cardiovascular, Anti-cold, Anti-Asthmatic and Antibiotic segments. NATCO has the credit of having pioneered Time Release Technology in India.
The Journey:- NATCO PHARMA was ranked 82nd in sales among Indian Pharmaceutical companies in 1994. NATCO also has the credit of being one of the largest contract manufacturers in India. Some of the well-known companies like Ranbaxy, Dr. Reddy’s Laboratories, John Wyeth etc. get their products manufactured by NATCO. NATCO PHARMA grew in size when three companies merged with it.
NATCO Parenterals Limited
Dr. Karanth Pharma Labs Private Limited
NATCO Laboratories Limited
Today:- NATCO PHARMA LIMITED, which began its operations as a single unit with 20 employees, today has four manufacturing facilities and employs around 1500 people. It has an on-line data for Analysis and decision making. Consistently ranked among the fastest growing pharmaceutical companies in the country, Natco is utilizing its collective experience to kick start its future plans as a global company. Respected for Quality, Performance, Care, Responsibility and for creation and maximization of wealth for its shareholders NATCO Pharma Limited, the post-merger organization represents a strategic stage in NATCO’s constant evolution as the Complete Pharma Company.
TIGI
URINAT
PRIMANAT
AMINAT
VORIZOL
NATCLOVIR
NATFLU
X-VIR
BUNIDE-CR
OMENAT
NATZOLD
BANDRONE 150
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is this redistributing the game…
“From illness to wellness” – this is what Apollo Life is all about. Ariz Rizvi, president of Apollo Life, gives his insight into the current state of occupational and rehabilitative…
Sridhar Ranganathan, managing director of Allergan, explains how the affiliate revolutionized the ophthalmologic market in India and how it engages with the different stakeholders, ranging from government institutions to the…
Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign – and both Indian companies and multinationals implanted in the world’s second most populous…
A strong advocate for women’s health and the first managing director of Roche Diagnostics India to be under 40 years old, Dr. Shravan Subramanyam shares his insights on the Indian…
With his over 25 years’ experience in running growing businesses and establishing start-ups, Ranjit Madan, CEO of the Life Sciences Sector Skill Development Council (LSSSDC), explains the journey of the…
Dilip G Shah, secretary-general of the Indian Pharmaceutical Alliance (IPA) and member of the Expert Review Committee on Access to Medicine (ATM), discusses the association’s commitment to assisting the Indian…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the leading country in its region. Despite the prevalence…
As a young pathbreaking transformer in the Indian pharmaceutical landscape, Yogesh Agrawal, managing director of Ajanta Pharma Ltd., shares his desire to accelerate the company’s expansion in the US. Out…
Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the thriving visual care industry which has allowed the company to launch 31 intraocular…
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based pharmaceutical companies in India, putting the patient at the center of all that they do is…
Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges…
See our Cookie Privacy Policy Here
